Home › Companies › SUTRO BIOPHARMA INC. › 2024-2025

SUTRO BIOPHARMA INC. 2024-2025 Proxy Voting Records

Compiled from SEC Form N-PX filings and SUTRO BIOPHARMA INC.’s Form 8-K, filed June 10, 2025 (Item 5.07 on EDGAR). Page generated October 14, 2026.

6Ballot items
109Asset managers
757Fund votes
June 6, 2025Meeting date

Results at a glance

Meeting of June 6, 2025: 6 items on SUTRO BIOPHARMA INC.’s Form 8-K, filed June 10, 2025: 6 without a stated outcome.

Material dissent

Elect Director: Heidi Hunter 57% of votes cast Outcome not stated Director under 80%
Elect Director: Jon Wigginton 57% of votes cast Outcome not stated Director under 80%
Elect Director: Michael Dybbs 56% of votes cast Outcome not stated Director under 80%

Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided

Proxy season: 2023-2024 2024-2025

Explore SUTRO BIOPHARMA INC. in the interactive database Compare manager voting policies

Official 2024-2025 meeting results reported by SUTRO BIOPHARMA INC.

These tallies are SUTRO BIOPHARMA INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 10, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

SUTRO BIOPHARMA INC. — official shareholder meeting results, meeting held June 6, 2025
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Support (of votes cast)	Reported outcome	Voting standard
Elect Director: Heidi Hunter	31,491,009	--	--	24,026,714	12,503,128	57%	Not verified	—
Elect Director: Jon Wigginton	31,496,677	--	--	24,021,046	12,503,128	57%	Not verified	—
Elect Director: Michael Dybbs	31,145,398	--	--	24,372,325	12,503,128	56%	Not verified	—
2. Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025	67,419,553	203,267	398,031	--	--	99.6%	Not verified	—
3. Approval, on a non-binding advisory basis, of the compensation of the Company's named executive officers as disclosed in the proxy statement for the Annual Meeting	42,988,166	12,355,370	174,187	--	12,503,128	78%	Not verified	—
4. Approval of the amendment of the Company's Restated Certificate of Incorporation (the " Charter ") to effect a reverse stock split of the Company's outstanding shares of common stock at a ratio of any whole number between 1-for-5 and 1-for-25, with the exac	57,705,935	10,131,760	183,156	--	--	85%	Not verified	—

Source: SUTRO BIOPHARMA INC., Form 8-K, filed with the SEC on June 10, 2025 — read the filing on EDGAR.

How asset managers voted at the SUTRO BIOPHARMA INC. 2024-2025 meeting

Each item below shows how the 109 asset managers that disclosed a SUTRO BIOPHARMA INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.

1. Elect Director: Heidi Hunter

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 3 wordings of this item as funds reported it.

57% Majority: yes · of votes cast

FOR 57%WITHHELD

FOR: 31,491,009WITHHELD: 24,026,714

Details: description as filed, official tally, votes by 36 asset managers

Description as filed by funds: Election of Class I Directors: Heidi Hunter

SUTRO BIOPHARMA INC.’s own tally for this item (“Elect Director: Heidi Hunter”): 31,491,009 for, 24,026,714 withheld, per its Form 8-K filed June 10, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 57% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 36 asset managers below reported 12,070,917 for, 734,838 withheld, 185,747 abstained.

FOR

FOR: 12,070,917ABSTAIN: 185,747WITHHOLD: 734,838

Largest asset managers voting on “Election of Class I Directors: Heidi Hunter” at SUTRO BIOPHARMA INC., 2024-2025
Asset manager	For	Abstain	Withheld	Vote
Vanguard	4,577,342	0	0	For
BlackRock	3,456,173	0	0	For
Fidelity	1,696,246	0	500	For
Goldman Sachs	890,665	0	0	For
Dimensional	0	0	395,450	Withhold
Equitable	151,381	0	96,370	Mixed
Prudential/PGIM	226,000	0	14,430	Mixed
TIAA	234,550	0	0	For
Charles Schwab	199,901	0	0	For
Nationwide	156,463	0	0	For
QUANTITATIVE MASTER SERIES LLC	149,383	0	0	For
ETF Series Solutions	0	136,623	0	Abstain
Aberdeen	0	0	69,389	Withhold
Lincoln Financial	60,700	0	2,078	For
ALPS ETF Trust	0	0	61,267	Withhold
Global X	48,431	0	0	For
Invesco	45,692	0	0	For
Pacific Life	44,834	0	0	For
AIG/SunAmerica	0	0	40,104	Withhold
Bridge Builder Trust	36,575	0	0	For
Northern Trust	31,730	0	0	For
John Hancock	0	31,500	0	Abstain
Voya	24,466	0	0	For
ProShares	0	0	19,884	Withhold
Jackson National	0	17,624	0	Abstain

Showing the 25 largest of 36 asset managers. See all 36 in the interactive database.

2. Elect Director: Jon Wigginton

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 3 wordings of this item as funds reported it.

57% Majority: yes · of votes cast

FOR 57%WITHHELD

FOR: 31,496,677WITHHELD: 24,021,046

Details: description as filed, official tally, votes by 36 asset managers

Description as filed by funds: Election of Class I Directors: Jon Wigginton, M.D.

SUTRO BIOPHARMA INC.’s own tally for this item (“Elect Director: Jon Wigginton”): 31,496,677 for, 24,021,046 withheld, per its Form 8-K filed June 10, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

The 36 asset managers below reported 12,070,917 for, 734,838 withheld, 185,747 abstained.

FOR

FOR: 12,070,917ABSTAIN: 185,747WITHHOLD: 734,838

Largest asset managers voting on “Election of Class I Directors: Jon Wigginton, M.D.” at SUTRO BIOPHARMA INC., 2024-2025
Asset manager	For	Abstain	Withheld	Vote
Vanguard	4,577,342	0	0	For
BlackRock	3,456,173	0	0	For
Fidelity	1,696,246	0	500	For
Goldman Sachs	890,665	0	0	For
Dimensional	0	0	395,450	Withhold
Equitable	151,381	0	96,370	Mixed
Prudential/PGIM	226,000	0	14,430	Mixed
TIAA	234,550	0	0	For
Charles Schwab	199,901	0	0	For
Nationwide	156,463	0	0	For
QUANTITATIVE MASTER SERIES LLC	149,383	0	0	For
ETF Series Solutions	0	136,623	0	Abstain
Aberdeen	0	0	69,389	Withhold
Lincoln Financial	60,700	0	2,078	For
ALPS ETF Trust	0	0	61,267	Withhold
Global X	48,431	0	0	For
Invesco	45,692	0	0	For
Pacific Life	44,834	0	0	For
AIG/SunAmerica	0	0	40,104	Withhold
Bridge Builder Trust	36,575	0	0	For
Northern Trust	31,730	0	0	For
John Hancock	0	31,500	0	Abstain
Voya	24,466	0	0	For
ProShares	0	0	19,884	Withhold
Jackson National	0	17,624	0	Abstain

Showing the 25 largest of 36 asset managers. See all 36 in the interactive database.

3. Elect Director: Michael Dybbs

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 3 wordings of this item as funds reported it.

56% Majority: yes · of votes cast

FOR 56%WITHHELD

FOR: 31,145,398WITHHELD: 24,372,325

Details: description as filed, official tally, votes by 36 asset managers

Description as filed by funds: Election of Class I Directors: Michael Dybbs, Ph.D.

SUTRO BIOPHARMA INC.’s own tally for this item (“Elect Director: Michael Dybbs”): 31,145,398 for, 24,372,325 withheld, per its Form 8-K filed June 10, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 56% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 36 asset managers below reported 12,039,187 for, 766,568 withheld, 185,747 abstained.

FOR

FOR: 12,039,187ABSTAIN: 185,747WITHHOLD: 766,568

Largest asset managers voting on “Election of Class I Directors: Michael Dybbs, Ph.D.” at SUTRO BIOPHARMA INC., 2024-2025
Asset manager	For	Abstain	Withheld	Vote
Vanguard	4,577,342	0	0	For
BlackRock	3,456,173	0	0	For
Fidelity	1,696,246	0	500	For
Goldman Sachs	890,665	0	0	For
Dimensional	0	0	395,450	Withhold
Equitable	151,381	0	96,370	Mixed
Prudential/PGIM	226,000	0	14,430	Mixed
TIAA	234,550	0	0	For
Charles Schwab	199,901	0	0	For
Nationwide	156,463	0	0	For
QUANTITATIVE MASTER SERIES LLC	149,383	0	0	For
ETF Series Solutions	0	136,623	0	Abstain
Aberdeen	0	0	69,389	Withhold
Lincoln Financial	60,700	0	2,078	For
ALPS ETF Trust	0	0	61,267	Withhold
Global X	48,431	0	0	For
Invesco	45,692	0	0	For
Pacific Life	44,834	0	0	For
AIG/SunAmerica	0	0	40,104	Withhold
Bridge Builder Trust	36,575	0	0	For
Northern Trust	0	0	31,730	Withhold
John Hancock	0	31,500	0	Abstain
Voya	24,466	0	0	For
ProShares	0	0	19,884	Withhold
Jackson National	0	17,624	0	Abstain

Showing the 25 largest of 36 asset managers. See all 36 in the interactive database.

4. 4. Approval of the amendment of the Company's Restated Certificate of Incorporation (the " Charter ") to effect a…

Outcome not verifiedCAPITAL STRUCTUREReported outcome: Not verified

Combines 2 wordings of this item as funds reported it.

85% Majority: yes · of votes cast

FOR 85%AGAINST

FOR: 57,705,935AGAINST: 10,131,760

Details: description as filed, official tally, votes by 36 asset managers

Description as filed by funds: To approve an amendment to our Restated Certificate of Incorporation to effect a reverse stock split of our outstanding shares of common stock at a ratio of any whole number between 1-for-5 and 1-for-25, with the exact ratio determined by the board of directors in its discretion, subject to the board of directors authority to abandon such amendment.

SUTRO BIOPHARMA INC.’s own tally for this item (“4. Approval of the amendment of the Company's Restated Certificate of Incorporation (the " Charter ") to effect a reverse stock split of the Company's outstanding shares of common stock at a ratio of any whole number bet”): 57,705,935 for, 10,131,760 against, per its Form 8-K filed June 10, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 85% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 36 asset managers below reported 12,991,502 for.

FOR

FOR: 12,991,502

Largest asset managers voting on “To approve an amendment to our Restated Certificate of Incorporation to effect a reverse stock split of our ou” at SUTRO BIOPHARMA INC., 2024-2025
Asset manager	For	Vote
Vanguard	4,577,342	For
BlackRock	3,456,173	For
Fidelity	1,696,746	For
Goldman Sachs	890,665	For
Dimensional	395,450	For
Equitable	247,751	For
Prudential/PGIM	240,430	For
TIAA	234,550	For
Charles Schwab	199,901	For
Nationwide	156,463	For
QUANTITATIVE MASTER SERIES LLC	149,383	For
ETF Series Solutions	136,623	For
Aberdeen	69,389	For
Lincoln Financial	62,778	For
ALPS ETF Trust	61,267	For
Global X	48,431	For
Invesco	45,692	For
Pacific Life	44,834	For
AIG/SunAmerica	40,104	For
Bridge Builder Trust	36,575	For
Northern Trust	31,730	For
John Hancock	31,500	For
Voya	24,466	For
ProShares	19,884	For
Jackson National	17,624	For

Showing the 25 largest of 36 asset managers. See all 36 in the interactive database.

5. 3. Approval, on a non-binding advisory basis, of the compensation of the Company's named executive officers as…

Outcome not verified Fund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Not verified

Combines 4 wordings of this item as funds reported it.

78% Majority: yes · of votes cast

FOR 78%AGAINST

FOR: 42,988,166AGAINST: 12,355,370

Details: description as filed, official tally, votes by 109 asset managers

Description as filed by funds: TO APPROVE, ON A NON-BINDING, ADVISORY BASIS, THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS.

SUTRO BIOPHARMA INC.’s own tally for this item (“3. Approval, on a non-binding advisory basis, of the compensation of the Company's named executive officers as disclosed in the proxy statement for the Annual Meeting”): 42,988,166 for, 12,355,370 against, per its Form 8-K filed June 10, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 78% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 36 asset managers voting on “TO APPROVE, ON A NON-BINDING, ADVISORY BASIS, THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS.” at SUTRO BIOPHARMA INC., 2024-2025
Asset manager	For	Against	Vote
Vanguard	4,577,342	0	For
BlackRock	3,456,173	0	For
Fidelity	1,696,746	0	For
Goldman Sachs	890,665	0	For
Dimensional	0	395,450	Against
Equitable	247,751	0	For
Prudential/PGIM	226,000	14,430	Mixed
TIAA	234,550	0	For
Charles Schwab	199,901	0	For
Nationwide	156,463	0	For
QUANTITATIVE MASTER SERIES LLC	149,383	0	For
ETF Series Solutions	136,623	0	For
Aberdeen	69,389	0	For
Lincoln Financial	60,700	2,078	For
ALPS ETF Trust	61,267	0	For
Global X	48,431	0	For
Invesco	0	45,692	Against
Pacific Life	44,834	0	For
AIG/SunAmerica	40,104	0	For
Bridge Builder Trust	36,575	0	For
Northern Trust	31,730	0	For
John Hancock	31,500	0	For
Voya	24,466	0	For
ProShares	19,884	0	For
Jackson National	0	17,624	Against

Fund voting reports, all 36 managers: 12,516,228 for, 475,274 against. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports: 89 asset managers voting on “TO APPROVE, ON A NON-BINDING, ADVISORY BASIS, THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS.” at SUTRO BIOPHARMA INC., 2024-2025
Asset manager	For	Against	Withheld	Vote
SUVRETTA CAPITAL MANAGEMENT, LLC	0	7,424,745	0	Against
Kynam Capital Management, LP	0	0	3,684,133	Withhold
RA CAPITAL MANAGEMENT, L.P.	3,341,169	0	0	For
Eversept Partners, LP	2,292,261	0	0	For
Samsara BioCapital, LLC	2,196,814	0	0	For
BlackRock	2,002,327	0	0	For
ADAGE CAPITAL PARTNERS GP, L.L.C.	2,000,000	0	0	For
GEODE CAPITAL MANAGEMENT, LLC	1,905,304	0	0	For
Vestal Point Capital, LP	1,685,252	0	0	For
State Street	1,565,359	0	0	For
Velan Capital Investment Management LP	1,030,000	0	0	For
AQR	641,819	0	0	For
Prudential/PGIM	488,660	20,100	0	For
DAFNA Capital Management LLC	0	437,079	0	Against
Renaissance	389,861	0	0	For
Northern Trust	361,231	0	0	For
Asset Management One Co., Ltd.	352,949	0	0	For
Affinity Asset Advisors, LLC	304,955	0	0	For
Goldman Sachs	297,133	0	0	For
Nuveen	290,897	0	0	For
MELLON INVESTMENTS Corp	0	272,532	0	Against
Charles Schwab	199,901	0	0	For
Dimensional	0	162,708	0	Against
STRS OHIO	152,800	0	0	For
Two Sigma	141,764	0	0	For

Institutional-manager reports, all 89 managers: 22,709,123 for, 8,437,181 against, 3,684,133 withheld. Showing the 25 largest; see all in the interactive database.

6. 2. Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm…

Outcome not verifiedAUDIT-RELATEDReported outcome: Not verified

99.6% Majority: yes · of votes cast

FOR 99.6%

FOR: 67,419,553AGAINST: 203,267

Details: description as filed, official tally, votes by 36 asset managers

Description as filed by funds: TO RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2025.

SUTRO BIOPHARMA INC.’s own tally for this item (“2. Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025”): 67,419,553 for, 203,267 against, per its Form 8-K filed June 10, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.6% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 36 asset managers below reported 12,991,172 for, 330 against.

FOR

FOR: 12,991,172AGAINST: 330

Largest asset managers voting on “TO RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FI” at SUTRO BIOPHARMA INC., 2024-2025
Asset manager	For	Vote
Vanguard	4,577,342	For
BlackRock	3,456,173	For
Fidelity	1,696,746	For
Goldman Sachs	890,665	For
Dimensional	395,450	For
Equitable	247,751	For
Prudential/PGIM	240,430	For
TIAA	234,550	For
Charles Schwab	199,901	For
Nationwide	156,463	For
QUANTITATIVE MASTER SERIES LLC	149,383	For
ETF Series Solutions	136,623	For
Aberdeen	69,389	For
Lincoln Financial	62,778	For
ALPS ETF Trust	61,267	For
Global X	48,431	For
Invesco	45,692	For
Pacific Life	44,834	For
AIG/SunAmerica	40,104	For
Bridge Builder Trust	36,575	For
Northern Trust	31,730	For
John Hancock	31,500	For
Voya	24,466	For
ProShares	19,884	For
Jackson National	17,624	For

Showing the 25 largest of 36 asset managers. See all 36 in the interactive database.

Largest SUTRO BIOPHARMA INC. shareholders voting in 2024-2025

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 84,461,365 shares outstanding at the time of that meeting.

Fund voting reports: top SUTRO BIOPHARMA INC. shareholders by shares voted on “TO APPROVE, ON A NON-BINDING, ADVISORY BASIS, THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS.”, 2024-2025
#	Asset manager	% of shares outstanding
1	Vanguard	5.42%
2	BlackRock	4.09%
3	Fidelity	2.01%
4	Goldman Sachs	1.05%
5	Dimensional	0.47%
6	Equitable	0.29%
7	Prudential/PGIM	0.28%
8	TIAA	0.28%
9	Charles Schwab	0.24%
10	Nationwide	0.19%

Institutional-manager reports: top SUTRO BIOPHARMA INC. shareholders by shares voted on “TO APPROVE, ON A NON-BINDING, ADVISORY BASIS, THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS.”, 2024-2025
#	Asset manager	% of shares outstanding
1	SUVRETTA CAPITAL MANAGEMENT, LLC	8.79%
2	Kynam Capital Management, LP	4.36%
3	RA CAPITAL MANAGEMENT, L.P.	3.96%
4	Eversept Partners, LP	2.71%
5	Samsara BioCapital, LLC	2.60%
6	BlackRock	2.37%
7	ADAGE CAPITAL PARTNERS GP, L.L.C.	2.37%
8	GEODE CAPITAL MANAGEMENT, LLC	2.26%
9	Vestal Point Capital, LP	2.00%
10	State Street	1.85%

Reported SUTRO BIOPHARMA INC. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.

SUTRO BIOPHARMA INC. holdings and ownership disclosed for the 2024-2025 proxy season
Holder	% outstanding	Disclosure
BlackRock	7.35%	13F
Suvretta Capital Management, LLC	6.84%	DEF14A
RA Capital Management, L.P.	5.25%	DEF14A
Vanguard Group	5.20%	13F
William J. Newell	2.32%	DEF14A
Goldman Sachs	2.03%	13F
State Street	1.99%	13F
Nuveen	1.57%	13F
BVF PARTNERS L P/IL	1.48%	13G
Affinity Asset Advisors, LLC	1.27%	13G

Percentages above are of 84,461,365 shares outstanding, as reported by SUTRO BIOPHARMA INC. on its Form 10-Q dated May 2, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from SUTRO BIOPHARMA INC.’s 10-Q dated May 2, 2025. This page is a static snapshot rebuilt weekly on October 14, 2026; a live search always shows the current data.

At SUTRO BIOPHARMA INC.'s shareholder meeting held June 6, 2025, in the 2024-2025 proxy season, 109 asset managers reported how they voted on 6 ballot items in their SEC Form N-PX filings, covering 757 separate fund positions. On the most widely held item on that ballot — TO APPROVE, ON A NON-BINDING, ADVISORY BASIS, THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS. — FOR was 78% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: SUTRO BIOPHARMA INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 10, 2025.

SUTRO BIOPHARMA INC. proxy season coverage: 2023-2024 · 2024-2025 (this page).

Download data (CSV): ballot items · votes by manager · column guide.